Anti-PD-L1 therapy yielded durable responses in early NSCLC trials

SAN DIEGO – Results from studies conducted to date indicate that anti-PD-L1 therapy is well tolerated in patients with non–small cell lung cancer, with rapid response rates.

In fact, responses are...